Lisinopril
FDA-approved product (tablet, oral), marketed as Lisinopril, Prinivil, Qbrelis and 1 more.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 1 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Cardiovascular disease
- Congestive heart failure
- Diabetes mellitus
- Heart failure
- Hypertension
- Myocardial infarction
- Stroke
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Ace inhibitors, plain
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.
AI-predicted activity
AI prediction · nothing measured- MRSA39.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- E. coli29.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae23.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis65.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Lisinopril with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Pafolacianine SodiumExisting use: Other diagnostic agents65.1% AI-predicted activityagainst M. tuberculosis1 registered study
- Avatrombopag MaleateExisting use: Hemorrhage, Liver disease, Thrombocytopenia65.0% AI-predicted activityagainst M. tuberculosis6 registered studies
- BumetanideExisting use: Cardiovascular disease, Congestive heart failure, Heart failure and 2 more64.9% AI-predicted activityagainst M. tuberculosis49 registered studies
- LetermovirExisting use: Cytomegalovirus infection, Infection, Viral disease64.9% AI-predicted activityagainst M. tuberculosis50+ registered studies
- ThioridazineExisting use: Psychosis64.8% AI-predicted activityagainst M. tuberculosis11 registered studies
- MethyclothiazideExisting use: Cardiovascular disease64.7% AI-predicted activityagainst M. tuberculosis5 registered studies
- FurosemideExisting use: Cardiovascular disease, Cirrhosis of liver, Congestive heart failure and 5 more64.7% AI-predicted activityagainst M. tuberculosis50+ registered studies
- EnzalutamideExisting use: Cancer, Metastatic prostate cancer, Neoplasm and 4 more64.7% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Irinotecan HydrochlorideExisting use: Adenocarcinoma, Cancer, Carcinoma and 4 more64.6% AI-predicted activityagainst M. tuberculosis50+ registered studies
- DactinomycinExisting use: Kidney Wilms tumor, Neoplasm64.6% AI-predicted activityagainst M. tuberculosis50+ registered studies
- LemborexantExisting use: Insomnia64.6% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Cabozantinib S-MalateExisting use: Cancer, Clear cell renal carcinoma, Hepatocellular carcinoma and 7 more64.4% AI-predicted activityagainst M. tuberculosis45 registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Remission From Stage D Heart Failure
NCT01774656 · start 2013-01
Registered record
- Registry ID
- NCT01774656
- Conditions
- Heart Failure NYHA Class III; Heart Failure NYHA Class IV
- Interventions
- Pharmacological Treatment
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Unknown
- Start
- 2013-01
- Completion
- 2017-12
- Enrolment
- 40
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHeart Failure NYHA Class III; Heart Failure NYHA Class IVInterventionPharmacological TreatmentPhasePhase 4Registry statusUnknownNon-invasive Haemodynamic Assessment in Hypertension
NCT01996085 · start 2013-01
Registered record
- Registry ID
- NCT01996085
- Conditions
- Arterial Hypertension
- Interventions
- lisinopril; Telmisartan; Nebivolol; Indapamide/hydrochlorothiazide; Amlodipine; lisinopril; Telmisartan; Nebivolol; Indapamide/hydrochlorothiazide; Amlodipine
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2013-01
- Completion
- 2017-12
- Enrolment
- 144
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionArterial HypertensionInterventionlisinopril; Telmisartan; Nebivolol; Indapamide/hydrochlorothiazide +6 morePhaseNot applicableRegistry statusCompletedSingle Pill to Avert Cardiovascular Events
NCT01313702 · start 2012-10
Registered record
- Registry ID
- NCT01313702
- Conditions
- Cardiovascular Disease
- Interventions
- polipillV1; polipillV2; usual care
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Withdrawn
- Start
- 2012-10
- Completion
- 2014-07
- Enrolment
- 0
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCardiovascular DiseaseInterventionpolipillV1; polipillV2; usual carePhasePhase 3Registry statusWithdrawnThe Renin-Angiotensin-Aldosterone System and Parathyroid Hormone Control: The RAAS-PARC Study
NCT01691781 · start 2012-10
Registered record
- Registry ID
- NCT01691781
- Conditions
- Hyperparathyroidism
- Interventions
- Lisinopril
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2012-10
- Completion
- 2016-12
- Enrolment
- 41
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHyperparathyroidismInterventionLisinoprilPhaseNot applicableRegistry statusCompletedBioequivalence Study of Lisinopril and Hydrochlorothiazide Tablets (20+25) mg Under Fasting Conditions
NCT01831700 · start 2012-10
Registered record
- Registry ID
- NCT01831700
- Conditions
- Fasting
- Interventions
- Lisinopril and Hydrochlorothiazide Tablets (20+25) mg; Zestoretic® 20/25 lisinopril/hydrochlorothiazide Tablets
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2012-10
- Completion
- 2012-10
- Enrolment
- 48
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionFastingInterventionLisinopril and Hydrochlorothiazide Tablets (20+25) mg; Zestoretic® 20/25 lisinopril/hydrochlorothiazide TabletsPhasePhase 1Registry statusCompletedBioequivalence Study of Lisinopril Tablets 40 mg Under Fasting Condition
NCT01735318 · start 2012-06
Registered record
- Registry ID
- NCT01735318
- Conditions
- Fasting
- Interventions
- Lisinopril Tablets 40 mg; Lisinopril
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2012-06
- Completion
- 2012-08
- Enrolment
- 40
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionFastingInterventionLisinopril Tablets 40 mg; LisinoprilPhasePhase 1Registry statusCompletedBioequivalence Study of Lisinopril Tablets 40 mg Under Fed Condition
NCT01735344 · start 2012-06
Registered record
- Registry ID
- NCT01735344
- Conditions
- Fed
- Interventions
- Lisinopril Tablets 40 mg; Lisinopril
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2012-06
- Completion
- 2012-08
- Enrolment
- 40
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionFedInterventionLisinopril Tablets 40 mg; LisinoprilPhasePhase 1Registry statusCompletedIs There a Benefit to Optimize Heart Failure (HF) Treatment in Aged Over 80 Year's Old Patients?
NCT01437371 · start 2011-08
Registered record
- Registry ID
- NCT01437371
- Conditions
- Heart Failure
- Interventions
- - Angiotensin conversing enzyme inhibitors: enalapril, captopril, lisinopril, ramipril, trandolapril.
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2011-08
- Completion
- 2014-06
- Enrolment
- 35
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHeart FailureIntervention- Angiotensin conversing enzyme inhibitors: enalapril, captopril, lisinopril, ramipril, trandolapril.PhasePhase 3Registry statusCompletedA Study of the Effect of LY2189265 on Two Blood Pressure Drugs
NCT01324388 · start 2011-03
Registered record
- Registry ID
- NCT01324388
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- LY2189265; Metoprolol; Lisinopril; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2011-03
- Completion
- 2011-08
- Enrolment
- 51
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionDiabetes Mellitus, Type 2InterventionLY2189265; Metoprolol; Lisinopril; PlaceboPhasePhase 1Registry statusCompletedBenazepril Hydrochloride, Lisinopril, Ramipril, or Losartan Potassium in Treating Hypertension in Patients With Solid Tumors
NCT01234922 · start 2011-02
Registered record
- Registry ID
- NCT01234922
- Conditions
- Hypertension; Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- lisinopril; losartan potassium; laboratory biomarker analysis; benazepril hydrochloride; ramipril
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Terminated
- Start
- 2011-02
- Completion
- 2014-04
- Enrolment
- 6
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHypertension; Unspecified Adult Solid Tumor, Protocol SpecificInterventionlisinopril; losartan potassium; laboratory biomarker analysis; benazepril hydrochloride +1 morePhasePhase 2Registry statusTerminatedLisinopril or Coreg CR® in Reducing Side Effects in Women With Breast Cancer Receiving Trastuzumab
NCT01009918 · start 2010-03
Registered record
- Registry ID
- NCT01009918
- Conditions
- Breast Cancer; Cardiac Toxicity
- Interventions
- Coreg CR®; lisinopril; placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2010-03
- Completion
- 2018-11
- Enrolment
- 468
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBreast Cancer; Cardiac ToxicityInterventionCoreg CR®; lisinopril; placeboPhasePhase 2Registry statusCompletedBlood Pressure Effects of Nebivolol Versus Lisinopril in New Onset or Worsening Hypertension Induced by Bevacizumab
NCT01076140 · start 2010-02
Registered record
- Registry ID
- NCT01076140
- Conditions
- Hypertension
- Interventions
- Nebivolol; Lisinopril
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Withdrawn
- Start
- 2010-02
- Completion
- 2011-08
- Enrolment
- 0
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHypertensionInterventionNebivolol; LisinoprilPhaseNot applicableRegistry statusWithdrawnClinical Trial of Coenzyme Q10 and Lisinopril in Muscular Dystrophies
NCT01126697 · start 2010-02
Registered record
- Registry ID
- NCT01126697
- Conditions
- Duchenne Muscular Dystrophy; Becker Muscular Dystrophy; Limb Girdle Muscular Dystrophy
- Interventions
- Coenzyme Q10 and Lisinopril
- Study type
- INTERVENTIONAL
- Phase
- Phase 2 / Phase 3
- Registry status
- Completed
- Start
- 2010-02
- Completion
- 2017-12
- Enrolment
- 63
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionDuchenne Muscular Dystrophy; Becker Muscular Dystrophy; Limb Girdle Muscular DystrophyInterventionCoenzyme Q10 and LisinoprilPhasePhase 2 / Phase 3Registry statusCompletedPolypill For Prevention of Cardiovascular Disease
NCT00567307 · start 2009-01
Registered record
- Registry ID
- NCT00567307
- Conditions
- Cardiovascular Disease
- Interventions
- Red Heart Pill 2b (Polypill); Standard Practice
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2009-01
- Completion
- 2010-01
- Enrolment
- 216
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCardiovascular DiseaseInterventionRed Heart Pill 2b (Polypill); Standard PracticePhasePhase 2Registry statusCompletedPhysical and Chemical Study of Atherosclerosis Mechanisms
NCT01700075 · start 2009-01
Registered record
- Registry ID
- NCT01700075
- Conditions
- Myocardial Infarction; Coronary Artery Diseases; Diabetes Mellitus, Type 2; Atherosclerosis of Femoral Artery
- Interventions
- Conventional treatment; Weight loss treatment
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2009-01
- Completion
- 2011-12
- Enrolment
- 97
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMyocardial Infarction; Coronary Artery Diseases; Diabetes Mellitus, Type 2; Atherosclerosis of Femoral ArteryInterventionConventional treatment; Weight loss treatmentPhasePhase 4Registry statusCompleted